NDA/BLA filedconf 0.70

NDA/BLA filed

$NUVL · Nuvalent, Inc.

Event date

Date TBD

Sponsor runway

42 mo

$1.29B liquid

Evidence

“On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.”

Source: 8-K filed 2026-04-07View on EDGAR ↗0001861560-26-000003

Comparable historical nda/bla fileds· last 5 years · same event type

Ticker	Drug	Date	Outcome
$AXSM	—	2025-12-31	unknown
$RCKT	kresladi	2025-10-14	unknown
$ALDX	reproxalap	2025-07-17	unknown
$ETON	et-600	2025-07-08	unknown
$BCRX	orladeyo (berotralstat)	2025-05-14	unknown
$CORT	relacorilant	2025-03-03	unknown
$ALDX	reproxalap	2024-11-01	unknown
$AXSM	axs-07	2024-09-04	unknown
$RCKT	kresladi	2023-10-02	unknown
$GERN	imetelstat	2023-08-21	unknown

Recent insider activity· ±90 days

4 insiders · 0 buys · 13 sells

Exercise10b5-1

2026-05-04

Porter James Richard

President and CEO

30,000 @ $18.93$568K

Sell10b5-1

2026-05-04

Porter James Richard

President and CEO

2,111 @ $102.88$217K

Sell10b5-1

2026-05-04

Porter James Richard

President and CEO

17,353 @ $102.10$1.77M

Sell10b5-1

2026-05-04

Porter James Richard

President and CEO

7,429 @ $101.48$754K

Sell10b5-1

2026-05-04

Porter James Richard

President and CEO

1,408 @ $99.77$140K

Sell10b5-1

2026-05-04

Porter James Richard

President and CEO

1,699 @ $98.54$167K

Sell10b5-1

2026-05-01

Balcom Alexandra

Chief Financial Officer

124 @ $99.97$12K

Exercise10b5-1

2026-05-01

Balcom Alexandra

Chief Financial Officer

7,159 @ $1.08$8K

Exercise10b5-1

2026-05-01

Balcom Alexandra

Chief Financial Officer

4,271 @ $6.89$29K

Sell10b5-1

2026-05-01

Balcom Alexandra

Chief Financial Officer

3,872 @ $98.42$381K

Sell10b5-1

2026-05-01

Balcom Alexandra

Chief Financial Officer

7,434 @ $99.29$738K

Sell10b5-1

2026-04-30

Miller Deborah Ann

Chief Legal Officer

1,082 @ $99.57$108K

Sell10b5-1

2026-04-30

Miller Deborah Ann

Chief Legal Officer

4,418 @ $99.13$438K

Exercise10b5-1

2026-04-30

Miller Deborah Ann

Chief Legal Officer

5,500 @ $6.89$38K

Sell10b5-1

2026-04-29

Noci Darlene

Chief Development Officer

700 @ $100.14$70K

Sell10b5-1

2026-04-29

Noci Darlene

Chief Development Officer

300 @ $101.17$30K

Sell10b5-1

2026-04-29

Noci Darlene

Chief Development Officer

4,500 @ $99.35$447K

Exercise10b5-1

2026-04-29

Noci Darlene

Chief Development Officer

5,500 @ $27.85$153K

Date	Insider	Action	Shares	Price	Value
2026-05-04	Porter James RichardPresident and CEO	Exercise10b5-1	30,000	$18.93	$568K
2026-05-04	Porter James RichardPresident and CEO	Sell10b5-1	2,111	$102.88	$217K
2026-05-04	Porter James RichardPresident and CEO	Sell10b5-1	17,353	$102.10	$1.77M
2026-05-04	Porter James RichardPresident and CEO	Sell10b5-1	7,429	$101.48	$754K
2026-05-04	Porter James RichardPresident and CEO	Sell10b5-1	1,408	$99.77	$140K
2026-05-04	Porter James RichardPresident and CEO	Sell10b5-1	1,699	$98.54	$167K
2026-05-01	Balcom AlexandraChief Financial Officer	Sell10b5-1	124	$99.97	$12K
2026-05-01	Balcom AlexandraChief Financial Officer	Exercise10b5-1	7,159	$1.08	$8K
2026-05-01	Balcom AlexandraChief Financial Officer	Exercise10b5-1	4,271	$6.89	$29K
2026-05-01	Balcom AlexandraChief Financial Officer	Sell10b5-1	3,872	$98.42	$381K
2026-05-01	Balcom AlexandraChief Financial Officer	Sell10b5-1	7,434	$99.29	$738K
2026-04-30	Miller Deborah AnnChief Legal Officer	Sell10b5-1	1,082	$99.57	$108K
2026-04-30	Miller Deborah AnnChief Legal Officer	Sell10b5-1	4,418	$99.13	$438K
2026-04-30	Miller Deborah AnnChief Legal Officer	Exercise10b5-1	5,500	$6.89	$38K
2026-04-29	Noci DarleneChief Development Officer	Sell10b5-1	700	$100.14	$70K
2026-04-29	Noci DarleneChief Development Officer	Sell10b5-1	300	$101.17	$30K
2026-04-29	Noci DarleneChief Development Officer	Sell10b5-1	4,500	$99.35	$447K
2026-04-29	Noci DarleneChief Development Officer	Exercise10b5-1	5,500	$27.85	$153K

← All catalysts for $NUVL